Nagasaki University
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
1
Ending by 2030
Oct 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 14, 2027The maintenance fee for Novel Bisphosphonic Acid Derivative and Application for Same (US 10,532,065) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,481,893 | DNA capable of inducing osteoblast-specific expression In force · USPTO record | In force | USPTO record | |
| US 10,130,357 | Instrument for delivering a surgical thread In force · USPTO record | In force | USPTO record | |
| US 10,175,229 | Rapid method for measuring cytotoxicity in non-RI system In force · USPTO record | In force | USPTO record | |
| US 10,532,065 | Novel Bisphosphonic Acid Derivative and Application for Same In force · High confidence | In force | High confidence | |
| US 10,280,188 | Novel Fluorine-Containing Bisphosphonic Acid Derivative and Use Thereof In force · High confidence | In force | High confidence | |
| US 10,734,726 | Wideband planar circularly polarized antenna and antenna device In force · USPTO record | In force | USPTO record | |
| US 11,286,261 | Fourth-generation EGFR tyrosine kinase inhibitor In force · USPTO record | In force | USPTO record | |
| US 11,559,195 | Rigid Endoscope Cover and Endoscope Unit In force · High confidence | In force | High confidence | |
| US 12,280,099 | Dengue virus vaccine In force · USPTO record | In force | USPTO record | |
| US 12,478,645 | Method for manufacturing cell population including liver precursor cells In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 11: 8 patents in force now held by others · 29 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 11 abandoned · 12 no status recorded